GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regentis Biomaterials Ltd. RGNT · USD

US listing · 🇺🇸 United States

Compare

1.27

+6.72%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Regentis Biomaterials Ltd.

Its shares trade under the ticker RGNT. It has been listed since 4 December 2025.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
4 Dec 2025
Employees
8
Head office
12 HA'ILAN STREET, NORTHERN INDUSTRIAL, OR AKIVA
Incorporated in
L3
Classification
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Filer status
Non-accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Regentis Biomaterials Ltd. has a focus on regenerative medicine with products like Gelrin and GelrinC.
  • The company has a small team of 8 employees, indicating a lean operational structure.
  • GelrinC is in Phase II clinical trials for knee cartilage injuries, showing progress in development.

Weaknesses

  • The company's sector and industry are listed as unknown, indicating unclear market positioning.
  • The company has only 8 employees, which may limit its operational capacity and scalability.
  • The IPO is scheduled for 2025-12-04, suggesting it is not yet publicly traded and may lack market validation.

Opportunities

  • GelrinC's Phase II clinical trials could lead to successful commercialization and market entry.
  • The regenerative medicine sector is growing, offering potential for expansion and partnerships.
  • The company's focus on tissue repair solutions aligns with increasing demand for advanced medical treatments.

Threats

  • The company's unknown sector and industry may hinder investor interest and market analysis.
  • The small employee count of 8 may lead to challenges in meeting regulatory and market demands.
  • The upcoming IPO in 2025-12-04 carries risks if clinical trials fail or market conditions worsen.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.